Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald P Radich

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
Stem Cells (Dayton, Ohio)|June 28, 2008
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA librariesMerav Bar, Stacia K Wyman, Brian R Fritz, et al.
Blood|November 6, 2014
Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progressionPhilip A Beer, David J H F Knapp, Paul H Miller, et al.
Science Translational Medicine|March 1, 2013
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patientsAude G Chapuis, Gunnar B Ragnarsson, Hieu N Nguyen, et al.
Blood|July 7, 2012
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDSH Joachim Deeg, Bart L Scott, Min Fang, et al.
Nature Communications|April 28, 2016
Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable PdotsChun-Ting Kuo, Alison M Thompson, Maria Elena Gallina, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
Stem Cells (Dayton, Ohio)|June 28, 2008
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA librariesMerav Bar, Stacia K Wyman, Brian R Fritz, et al.
Blood|November 6, 2014
Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progressionPhilip A Beer, David J H F Knapp, Paul H Miller, et al.
Science Translational Medicine|March 1, 2013
Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patientsAude G Chapuis, Gunnar B Ragnarsson, Hieu N Nguyen, et al.
Blood|July 7, 2012
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDSH Joachim Deeg, Bart L Scott, Min Fang, et al.
Nature Communications|April 28, 2016
Optical painting and fluorescence activated sorting of single adherent cells labelled with photoswitchable PdotsChun-Ting Kuo, Alison M Thompson, Maria Elena Gallina, et al.
Leukemia|March 12, 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trialJerald P Radich, Andreas Hochhaus, Tamás Masszi, et al.
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
Journal of Cancer Research and Clinical Oncology|February 23, 2018
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom studyDavid M Ross, Tamas Masszi, María Teresa Gómez Casares, et al.
Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.
Pageof 21